.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

The Changing Landscape of Treatment for EGFR+ Lung Cancer

EP. 1: Significance of FLAURA in EGFR+ NSCLC

October 20th 2018

EP. 2: Osimertinib For Uncommon EGFR Mutations in NSCLC

October 20th 2018

EP. 3: Overcoming Resistance to EGFR Inhibitors in NSCLC

October 20th 2018

EP. 4: Managing Disease Progression in EGFR+ NSCLC

October 20th 2018

EP. 5: Emerging EGFR Inhibitors in NSCLC

October 20th 2018

EP. 6: Promising Treatment Combinations in EGFR+ NSCLC

October 20th 2018

EP. 7: EGFR Inhibitors as Adjuvant Therapy in NSCLC

October 20th 2018

EP. 8: Improving the Management of EGFR+ NSCLC

October 20th 2018